-
Specialties
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
5.0 /5( out of 39 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 17, 2024HUNTSMAN CANCER CENTERDr. Kinsey is the best! He works well with my medical team, is very responsive and cooperative. Not only does he listen to my concerns but his explanations are easy to understand and relatable. I just love him!!!!
October 04, 2024HUNTSMAN CANCER CENTERHe was prepared. He'd looked at my extensive medical history and was well prepared. He even reviewed the stuff I brought with me same day.
September 21, 2024HUNTSMAN CANCER CENTERDR. Kinsey listened to me & helped me make the right decision for my care. He made sure I had the best DR for my kind of surgery. I trust him completely.
September 14, 2024HUNTSMAN CANCER CENTERExcellent Dr
September 01, 2024HUNTSMAN CANCER CENTERDr. Kinsey is positive and friendly. He answers all my questions and is never in a rush. I am so lucky he's my doctor.
July 08, 2024HUNTSMAN CANCER CENTERDr Kinsey has consistently provided the top tier of care throughout the course of my medical treatment.
June 15, 2024HUNTSMAN CANCER CENTERDr Kinsey is the most wonderful doctor I have ever met. Not only is he an ultimate professional but also an extremely knowledgeable doctor in his field of practice. I will go back to him time and time again.
June 03, 2024HUNTSMAN CANCER CENTERHighly recommend
May 31, 2024HUNTSMAN CANCER CENTERDr Kinsey never rushes through an appointment. He always listens to me and answers all my questions.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Oncological Sciences -Adjunct Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Postdoctoral Fellowship Hematology/Oncology - Huntsman Cancer Institute Postdoctoral Fellow Fellowship Hematology/Oncology - Huntsman Cancer Institute Fellow Residency Internal Medicine - University of Utah School of Medicine Resident Professional Medical Genetics and Medicine - University of Rochester School of Medicine and Dentistry M.D., Ph.D. Undergraduate Cell Biology/Biochemistry - Bucknell University B.S. Selected Publications
Journal Article
- Ghazi PC, OToole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, Bogdan M, Smith BD, Lozano G, Flynn DL, Snyder EL, Kinsey CG, McMahon M (2024). Inhibition of ULK1/2 and KRAS(G12C) controls tumor growth in preclinical models of lung cancer. Elife, 13. ()
- Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, Kinsey CG, Adams DJ, Grossmann A, Mann MB, McMahon M (2021). Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Res, 82(22), 4261-4273. ()
- Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, Blumer KJ, Odelberg SJ, McMahon M (2020). Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition. Clin Cancer Res, 26(23), 6374-6386. ()
- Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M (2019). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep, 32(5), 107994. ()
- Kinsey C, Balakrishnan V, ODell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H (2014). Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep, 7(4), 1143-55. ()
- McMurray HR, Sampson ER, Compitello G, Kinsey C, Newman L, Smith B, Chen SR, Klebanov L, Salzman P, Yakovlev A, Land H (2008). Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature, 453(7198), 1112-6. ()
- Kinsey CG, Bussolati G, Bosco M, Kimura T, Pizzorno MC, Chernin MI, Cassoni P, Novak JF (2007). Constitutive and ligand-induced nuclear localization of oxytocin receptor. J Cell Mol Med, 11(1), 96-110. ()
- Takahashi M, Chernin MI, Yamamoto O, Tonzetich J, Kinsey CG, Novak JF (2002). Transformation of MC3T3-E1 cells following stress and transfection with pSV2neo plasmid. Anticancer Res, 22(2A), 585-98. ()
Review
- Foth M, Garrido-Laguna I, Kinsey CG (2021). Therapeutic Targeting of Autophagy in Pancreatic Cancer. [Review]. Surg Oncol Clin N Am, 30(4), 709-718. ()
- Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. [Review]. J Gastrointest Oncol, 9(6), 1014-1026. ()
Book Chapter
- Vaishnavi A, Kinsey CG, McMahon M (2023). Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse. In Cold Spring Harb Perspect Med. United States. ()
- Gilcrease GW, Kinsey C, Stenehjem D (2015). Environmental and genetic risk factors in hepatocellular carcinoma. In Torre A, Uscanga L (Eds.), Medicina Individualizada De La Evidencia A La Práctica ClÃnica (pp. 155-62). Permanyer México.
-
News & Podcasts
Huntsman Cancer Institute News
-
Clinical Trials
( out of 39 reviews )
Clinical Locations
Huntsman Cancer Institute - Cancer Hospital South
Clinic 3A, Gastrointestinal
Salt Lake City
801-587-4700
